Pacritinib Is a Potent ACVR1 Inhibitor with Significant Anemia Benefit in Patients with Myelofibrosis
Dr Stephen Oh reviews the use of pacritinib in patients with myelofibrosis and the impact on anemia. Funding supported by CTI Biopharma. Content independently developed by OncLive.
Funding supported by CTI Biopharma. Content independently developed by OncLive.
Related Videos
Related Content
